Literature DB >> 2545182

Modulation of gentamicin nephrotoxicity by chronic inhibition of angiotensin-I-converting enzyme in rat.

J P Morin1, N Thomas, H Toutain, H Borghi, J P Fillastre.   

Abstract

Perindopril, a new specific and potent inhibitor of angiotensin-I-converting enzyme, was used to evaluate the possible participation of inhibition of the renin-angiotensin system in the development of aminoglycoside-induced renal failure. Kidney function, morphology and biochemistry were evaluated at regular intervals throughout the study. Perindopril was given orally to rats at a daily dose of 2 mg/kg for 15 days prior to and during 15-day gentamicin treatment given intraperitoneally at a daily dose of 50 mg/kg. Perindopril treatment alone induced no modification in renal function or structure. Gentamicin treatment alone induced typical renal lesions which were scored as moderate and a slight but significant decrease in ACE blood levels. Concurrent treatment with perindopril and gentamicin induced a greater drop in ACE blood levels than after the administration of perindopril alone and produced more marked renal impairment than after the administration of gentamicin alone. These observations suggest that the integrity of the renin-angiotensin system may play an important role in limiting kidney injury during aminoglycoside-induced nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545182     DOI: 10.1007/BF00334634

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  38 in total

1.  Disposition of enalapril and enalaprilat in renal insufficiency.

Authors:  R J Fruncillo; M L Rocci; P H Vlasses; P Mojaverian; K Shepley; R A Clementi; A Oren; R D Smith; A E Till; L J Riley
Journal:  Kidney Int Suppl       Date:  1987-05       Impact factor: 10.545

2.  Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).

Authors:  T Unger; M Moursi; D Ganten; K Hermann; R E Lang
Journal:  J Cardiovasc Pharmacol       Date:  1986 Mar-Apr       Impact factor: 3.105

Review 3.  The renin-angiotensin system and nephron function heterogeneity.

Authors:  A Mimran; D Casellas
Journal:  Kidney Int Suppl       Date:  1987-05       Impact factor: 10.545

4.  Reversibility of gentamicin nephrotoxicity in rats: recovery during continuous drug administration.

Authors:  D N Gilbert; D C Houghton; W M Bennett; C E Plamp; K Reger; G A Porter
Journal:  Proc Soc Exp Biol Med       Date:  1979-01

Review 5.  Aminoglycoside nephrotoxicity.

Authors:  W M Bennett
Journal:  Nephron       Date:  1983       Impact factor: 2.847

6.  Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.

Authors:  M Laubie; P Schiavi; M Vincent; H Schmitt
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

7.  Calcium is a competitive inhibitor of gentamicin-renal membrane binding interactions and dietary calcium supplementation protects against gentamicin nephrotoxicity.

Authors:  H D Humes; M Sastrasinh; J M Weinberg
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

8.  Early effects of gentamicin, tobramycin, and amikacin on the human kidney.

Authors:  M E De Broe; G J Paulus; G A Verpooten; F Roels; N Buyssens; R Wedeen; F Van Hoof; P M Tulkens
Journal:  Kidney Int       Date:  1984-04       Impact factor: 10.612

9.  Mechanisms of the defect in glomerular ultrafiltration associated with gentamicin administration.

Authors:  C Baylis; H R Rennke; B M Brenner
Journal:  Kidney Int       Date:  1977-11       Impact factor: 10.612

10.  Tissue repair in rat kidney cortex after short treatment with aminoglycosides at low doses. A comparative biochemical and morphometric study.

Authors:  G Toubeau; G Laurent; M B Carlier; S Abid; P Maldague; J A Heuson-Stiennon; P M Tulkens
Journal:  Lab Invest       Date:  1986-04       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.